Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma

Inclusion Criteria: * Histological confirmed diagnosis of malignant peritoneal mesothelioma * Patients that are not eligible (or willing) to undergo cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) * Age ≥ 18 years old * Written informed consent according to the International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) and national/local regulations * Patients must be ambulatory, i.e. World Health Organization-Eastern Cooperative Oncology Group (WHO-ECOG) performance status 0 or 1 * Ability to return to the Erasmus Medical Center for adequate follow-up as required by this protocol * Patients must have normal organ function and adequate bone marrow reserve as assessed by the following laboratory requirements; absolute neutrophil count \>1.5 \* 10\^9/l, platelet count \>100\*10\^9/l and Hemoglobin \>6.0mmol /l. Patients must have a Bilirubin \<1½ x upper limit of normal (ULN), Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \<2.5 x ULN Exclusion Criteria: * Extra-abdominal disease/metastatic disease established by preoperative CT-scan of thorax-abdomen and/or PET-scan. Imaging not older than two months at time of surgery * Medical or psychological impediment to probable compliance with the protocol * Serious concomitant disease or active infections * History of auto-immune disease or organ allografts, or with active or chronic infection, including HIV and viral hepatitis * Serious intercurrent chron…